[go: up one dir, main page]

Azatian et al., 1994 - Google Patents

A study of the use of clonidine and naltrexone in the treatment of opioid addiction in the former USSR

Azatian et al., 1994

Document ID
990875731202735113
Author
Azatian A
Papiasvilli A
Joseph H
Publication year
Publication venue
Journal of addictive diseases

External Links

Snippet

Sixty-eight opioid addicts in Moscow voluntarily entered a two phase study that employed the medications clonidine and naltrexone to withdraw addicts from narcotics and naltrexone for mainenance therpay. Of the 44 subjects entering the withdrawal phase, only 3 completed …
Continue reading at www.tandfonline.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Silberstein et al. Repetitive intravenous DHE in the treatment of refractory headache
Akhondzadeh et al. Passionflower in the treatment of opiates withdrawal: a double‐blind randomized controlled trial
Freedman et al. Clinical studies of cyclazocine in the treatment of narcotic addiction
Azatian et al. A study of the use of clonidine and naltrexone in the treatment of opioid addiction in the former USSR
JP2008201799A (en) Cocaine dependence-treating medicine
Burke Palliative care: an update on “terminal restlessness”
Ward et al. Methadone maintenance therapy for opioid dependence: a guide to appropriate use
Jiménez‐Lerma et al. Nimodipine in opiate detoxification: a controlled trial
Vaughan et al. Opioid detoxification
Boyce et al. Effect of innappropriate naltrexone use in a heroin misuser
Lee Tackling subutex abuse in Singapore
Torrington et al. Buprenorphine 101: treating opioid dependence with buprenorphine in an office-based setting
Baltieri et al. Brazilian guideline for the treatment of patients with opioids dependence syndrome
Guo et al. Monthly take-home methadone maintenance regime for elderly opium-dependent users in Singapore
Welliver et al. Two new case reports of propofol abuse and a pattern analysis of the literature
Ketai Psychotropic drugs in the management of psychiatric emergencies
Resnick Prospects, problems, side effects, and safety of narcotic antagonists
Bailey Pharmacological treatments for substance use disorders
Parker et al. Epidemiology of Opioid Use and Smoking, Alcohol, and Polysubstance Use Among Persons Using Opioids
RU2183125C1 (en) Method to correct immune disorders at opium narcomania
Batta Heroin as Substance of Addiction
Shafti Methadone vs. Acetamin-ophen Codeine plus Clonidine, As Opioid Substitution Scheme: A Pilot Appraisal
Wilson et al. Anesthesia-assisted rapidopiate detoxification: A new procedure in the postanesthesia care unit
Stankiewicz et al. Methadone, Naltrexone, and Naloxone
Tilly et al. Naltrexone in the treatment of federal probationers